Table 3

Association between patient-reported outcomes and remission during 1 year of follow-upa
Measurements All Early remission Arm 1 Arm 2 OP group
Crude β (95% CI)
HAQ −0.31 (−0.36 to −0.26) −0.43 (−0.57 to −29) −0.45 (−0.58 to −0.32) 0.18 (−0.33 to −0.02)
MACTAR 7.8 (6.9 to 8.9)
PCS 6.2 (5.1 to 7.4) 10.2 (7.5 to 12.9) 8.9 (5.8 to 12.0) 4.5 (0.6 to 8.4)
MCS 0.8 (0.01 to 1.6)
Adjusted β (95% CI)
HAQ −0.30 (−0.35 to −0.25) −0.43 (−0.57 to −29) −0.45 (−0.58 to −0.32) 0.17 (−0.32 to −0.01)
MACTAR 8.1 (7.0 to 9.2)
PCS 6.0 (4.9 to 7.2) 9.9 (7.1 to 12.7) 9.1 (6.1 to 12.1) 4.2 (0.2 to 8.1)
MCS 0.8 (−0.01 to 1.7)

aCI: confidence interval; HAQ: Health Assessment Questionnaire; MACTAR: McMaster Toronto Arthritis Patient Preference Questionnaire; MCS: Mental Component Score of the 36-Item Short Form Health Survey; OP: outside protocol subgroup; PCS: Physical Component Score of the 36-Item Short Form Health Survey. Fixed effects were entered for time (study visits at 4 months, 8 months and 1 year) and mean baseline score of the assessed PRO. The analyses were also performed with adjustment (adjusted β) for ACPA status (positive or negative), sex (male or female), DAS at baseline and tender and swollen joint counts, and these were also entered into the analysis as fixed variables. For HAQ score and PCS, we stratified for treatment group (early remission, arm 1, arm 2 and OP subgroup) because there was a significant interaction between treatment group and achieving remission.

Heimans et al.

Heimans et al. Arthritis Research & Therapy 2013 15:R173   doi:10.1186/ar4361

Open Data